Free tool
FAERS Monitor: Cysto-Conray Ii
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017057 or its brand name (Cysto-Conray Ii, Iothalamate Meglumine). Reports on generic versions are filed under their own applications.
Reports
16
Serious
5
31% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- incorrect route of drug administration8
- wrong drug administered4
- anaphylactoid reaction2
- no adverse event2
- agranulocytosis1
- anaphylactic reaction1
- angioedema1
- cough1
- drug ineffective1
- expired product administered1
- fixed eruption1
- hypersensitivity1
- pyrexia1
- vomiting1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fixed eruption | 1 | 764.6 | 114.5 | 190 |
| anaphylactoid reaction | 2 | 639.2 | 174.8 | 716 |
| wrong drug administeredSignal | 4 | 590.3 | 252.6 | 1,801 |
| incorrect route of drug administrationSignal | 8 | 294.3 | 180.3 | 2,057 |
| agranulocytosis | 1 | 70.7 | 10.6 | 17 |
| expired product administered | 1 | 39.5 | 5.9 | 9 |
| angioedema | 1 | 29.7 | 4.5 | 6 |
| anaphylactic reaction | 1 | 23.8 | 3.6 | 5 |
| no adverse event | 2 | 14.5 | 4.0 | 14 |
| hypersensitivity | 1 | 7.1 | 1.1 | 1 |
| cough | 1 | 4.7 | 0.7 | 0 |
| pyrexia | 1 | 3.8 | 0.6 | 0 |
| vomiting | 1 | 2.8 | 0.4 | 0 |
| drug ineffective | 1 | 1.0 | 0.1 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.